Article in Cancer immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Emmanuel S AntonarakisDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-0031-9655
Jeffrey S MillerDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-0339-4944
Justin H HwangDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-1686-7103
Frank CichockiDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-3043-0653
Funding
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
Viral priming and targeting NK cells against solid tumor malignanciesR35CA197292 · NCI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2021
$6.2M
Bcl11b: A Master Transcription Factor Controlling Human NK Cell DevelopmentR01HL155150 · NHLBI · UNIVERSITY OF MINNESOTA · PI CICHOCKI, FRANK · 2021 to 2025
$1.6M
Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)R37CA288972 · NCI · UNIVERSITY OF MINNESOTA · PI Justin H. Hwang · 2024 to 2026
$1.1M
Tissue-Resident Adaptive CD56bright NK Cell Responses in CancerF30CA294723 · NCI · UNIVERSITY OF MINNESOTA · PI John Roy Lozada · 2024 to 2026
$142k
American Society of Hematology (ASH) HIP Medical Student AwardConquer Cancer Foundation (CCF) Medical Student RotationNational Cancer Institute (NCI) P01 CA65493NCI NIH HHS F30 CA294723NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA077598NCI NIH HHS R35 CA197292NCI NIH HHS R37 CA288972NHLBI NIH HHS R01 HL155150NIGMS NIH HHS T32 GM008244Prostate Cancer Foundation (PCF) Young Investigator AwardRandy Shaver Cancer Research and Community Fund (Randy Shaver Cancer Research & Community Fund)University of Minnesota Institute for Prostate and Urologic Cancers Philanthropic FundU.S. Department of Defense (DOD) Early Investigator Award W81XWH-22-1-0242U.S. Department of Defense (DOD) W81XWH-22-2-0025
6 · The paper itself
Abstract
Natural killer (NK) cells represent key effectors of antitumor immunity, yet emerging evidence highlights populations with distinct roles in cancer. Despite such expanded diversity within the NK cell repertoire, we lack an understanding of how this heterogeneity affects immune responses and downstream clinical outcomes. Using single-cell RNA sequencing, we systematically profiled NK cells across cancer and uncovered a dichotomous phenotypic and functional landscape of tumor-infiltrating NK cells shaped by opposing intrinsic signaling programs that drive the expression of IFNG or TGFB1. These divergent programs are associated with distinct transcription factor circuits that integrate cues within the tumor microenvironment and skew NK cells toward proinflammatory or suppressive functions. We found that the capacity for NK cells to engage in either functional direction is intrinsically linked to their phenotypic identity. Canonical NK cells recruited from circulation predominantly directed suppressive TGFB1 signals toward effector CD8+ T cells in tumors. Of note, these subsets exhibited higher TGFB1 expression than intratumoral myeloid cells across tumor types. In contrast, a tissue-resident (TR) adaptive subset exhibited exclusively proinflammatory IFNG-driven profiles and was associated with prolonged survival in both primary and metastatic tumor settings. Moreover, these TR adaptive NK cells, but not other subsets, were linked to response to immune checkpoint blockade. Collectively, our study reveals a previously unrecognized regulatory axis in NK cells that shapes NK cell diversity and augments broader antitumor immune responses.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors. · full record | OpenQuestion